RESUMEN
BACKGROUND: Alveolar soft part sarcoma (ASPS) is a very rare mesenchymal malignancy of uncertain origin. It mostly affects young people, with about a quarter of cases being diagnosed in children. CASE: An 11-year-old girl had a painless subcutaneous "lump" in the left elbow area. Imaging exams revealed a solid soft-tissue intramuscular mass of suspicious appearance. A surgical excision of lesion was performed. The biopsy consisted of a lobular tumor measuring 35 × 20 × 12â mm. Histology revealed an epithelioid-cell population arranged in organoid pseudoalveolar pattern. It immunohistochemically expressed TFE3 and harbored the ASPSCR1:: TFE3 gene fusion. A diagnosis of ASPS was established. Subsequently, a wide re-excision of the scar was performed without microscopic residual tumor. The patient is currently without evidence of local recurrence or metastasis. CONCLUSION: ASPS is considered an aggressive and prognostically unfavorable chemoresistant neoplasm. Children have a better prognosis compared to adults. Early detection of tumor in a localized stage with complete surgical removal remains a mainstay therapeutic option. Due to its tendency to late metastases, a long-term thorough follow-up of the patient is necessary.
Asunto(s)
Sarcoma de Parte Blanda Alveolar , Adulto , Femenino , Humanos , Niño , Adolescente , Sarcoma de Parte Blanda Alveolar/diagnóstico , Sarcoma de Parte Blanda Alveolar/genética , Sarcoma de Parte Blanda Alveolar/cirugía , Proteínas de Fusión Oncogénica , Fusión Génica , Pronóstico , Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice/genéticaRESUMEN
Anaplastic large cell lymphoma represents approximately 10-15 % of pediatric non-Hodgkin lymphomas. Leukemic presentation is very rare, and in particular, the null phenotype ALCL without typical anaplastic morphology together with aberrant expression of CD13 and/or CD11b represents a diagnostic challenge. We report a case of a 9 year-old boy with leukemic presentation of ALCL with the typical translocation t(2;5)(p23;q35); in this patient, the only positive antigens identified by immunophenotyping were CD13, NG2 HLA-DR, and CD38. To our knowledge, aberrant expression of NG2 has never been reported in ALCL cases (Tab. 1, Fig. 6, Ref. 20).
Asunto(s)
Antígenos/metabolismo , Antígenos CD13/metabolismo , Inmunofenotipificación , Linfoma Anaplásico de Células Grandes/diagnóstico , Proteoglicanos/metabolismo , Translocación Genética , Niño , Cromosomas Humanos Par 2 , Cromosomas Humanos Par 5 , Humanos , Linfoma Anaplásico de Células Grandes/genética , Linfoma Anaplásico de Células Grandes/inmunología , MasculinoRESUMEN
Acute lymphoblastic leukemia is the most common form of cancer in children. The 10-year event-free survival ranged from 77 to 85% after having achieved complete remission rates of 93% or higher. The main cause of treatment failure is relapse arising from outgrowth of residual leukemic cells that are refractory to therapy. An intense effort has been made to develop methods to determine the degree of minimal residual leukemia cells present in patients considered to be in morphological remission. Because of the strong correlation between minimal residual disease (MRD) levels and risk of relapse, monitoring of MRD provides unique information regarding treatment response. The MRD monitoring based on real-time quantitative PCR detection of patient-specific immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements is currently considered to be the most reliable tool for MRD-based diagnosis in ALL. Because the significance of MRD monitoring has been strongly supported by several studies and because it has been implemented in the latest protocols, there has been a significant effort to develop MRD monitoring in the Slovak Republic since 2005. Between October 2006 and December 2009, 50 children with ALL who were treated at three Slovak centers were included in the RQ PCR MRD pilot project. A total of 40 patients with BCP-ALL ( B cell precursor ALL) and 4 patients with T ALL were analyzed for Ig/TCR rearrangement. We identified 106 different rearrangements in the 44 ALL patients analyzed. Based on MRD stratification, we identified 26 patients who were stratified into the HRG ( high risk group) (n = 3; 11.5%), IRG ( intermediate risk group) (n = 14; 54%) and SRG ) standard risk group) (n = 9; 34.5%). Morphology-based risk stratification allows the identification of most HRG patients identified also by MRD-based stratification, but fails to discriminate the IRG assigned to therapy reduction. Patients in the SRG and the IRG could profit from MRD-based risk assignment
Asunto(s)
Reordenamiento Génico de Linfocito T , Reordenamiento Génico , Genes de Inmunoglobulinas , Reacción en Cadena de la Polimerasa/métodos , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Adolescente , Niño , Preescolar , Femenino , Humanos , Inmunofenotipificación , Lactante , Recuento de Leucocitos , Masculino , Neoplasia Residual/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunologíaRESUMEN
The tumor formation may be the earliest manifestation preceeding other symptoms, signs and bone marrow evidence of systemic malignancy - leukemia/lymphoma. Here we present three cases of systemic malignancy in which bone lesions were the first manifested signs of the disease. All three cases were thought to be orthopedic cases and had been treated as so without genuing improvement. We would like to draw an attention to children who present with multifocal musculoskeletal pain and the importance of whole-body scaning. We describe interesting cases of diffuse large cell lymphoma and leukemia that initially presented as primary osteolytic bone lesion and discuss the differential diagnosis, literature review of non-Hodgkin's lymphoma arising in bone as the primary site (Tab. 1, Fig. 3, Ref. 18). Full Text (Free, PDF) www.bmj.sk.
Asunto(s)
Linfoma de Células B Grandes Difuso/complicaciones , Osteólisis/complicaciones , Síndromes Paraneoplásicos/diagnóstico por imagen , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Adolescente , Niño , Femenino , Humanos , Masculino , Osteólisis/diagnóstico por imagen , Síndromes Paraneoplásicos/complicaciones , Cintigrafía , Imagen de Cuerpo EnteroRESUMEN
Tumor lysis syndrome (TLS) is caused by rapid tumor cell turnover resulting in a release of intracellular contents into the circulation, and subsequent numerous metabolic derangements (hyperkalemia, hypocalcemia, hyperphosphatemia, hyperuricemia). More than 90% of cases have laboratory manifestations, and only about 10% have clinical manifestations. The main complications are acute renal failure, cardiac arrhythmia and metabolic acidosis. The management of TLS consists of preventive measures in high-risk patients prior to cancer treatment as well as prompt initiation of supportive care for patients who develop acute tumor lysis syndrome during treatment. The traditional management consists of intravenous hydratation, urinary alkalinization, diuretics and control of hyperuricemia, electrolyte disturbances and dialysis if needed. The use of a new hypouricemic agent (rasburicase) in patients with TLS minimized the need for renal dialysis as well as reduced the incidence of complications seen in hyperproduction of uric acid to minimum (Tab. 4, Ref. 8). Full Text (Free, PDF) www.bmj.sk.
Asunto(s)
Síndrome de Lisis Tumoral/terapia , Niño , Preescolar , Femenino , Humanos , Leucemia/complicaciones , Linfoma/complicaciones , Masculino , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/prevención & control , Urato Oxidasa/uso terapéuticoAsunto(s)
Antifúngicos/administración & dosificación , Aspergilosis/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Neoplasias/complicaciones , Nistatina/administración & dosificación , Adolescente , Adulto , Anfotericina B/uso terapéutico , Antifúngicos/efectos adversos , Antifúngicos/uso terapéutico , Niño , Femenino , Fluconazol/uso terapéutico , Humanos , Liposomas , Masculino , Persona de Mediana Edad , Nistatina/efectos adversos , Insuficiencia del Tratamiento , Resultado del TratamientoRESUMEN
Amphotericin B (AmB) resistance in Candida spp. is very rare. Three cases of fungemia, due to amphotericin B-resistant Candida spp. in pediatric patients after previous neurosurgery for brain tumors, are reported. The Candida strains - one C. guillermondii, one C. lusitaniae, and one C. parapsilosis - showed minimum inhibitory concentrations (MICs) to AmB of 2-4 microg/ml. Two of the three patients had been pretreated with AmB for 5-11 days. All three patients were successfully treated with intravenous fluconazole (6-10 mg/kg per day) for 16-28 days, and all survived. Despite AmB resistance in Candida spp. being very rare, C. lusitaniae, C. guillermondii, and C. parapsilosis isolates in documented infections should be tested for AmB resistance, mainly in patients not responding to therapy with AmB.
Asunto(s)
Anfotericina B/farmacología , Antifúngicos/farmacología , Neoplasias Encefálicas/cirugía , Candida/efectos de los fármacos , Candidiasis/microbiología , Craneotomía , Infección Hospitalaria/microbiología , Fungemia/microbiología , Complicaciones Posoperatorias/microbiología , Adolescente , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Neoplasias Encefálicas/complicaciones , Candida/aislamiento & purificación , Candidiasis/tratamiento farmacológico , Cateterismo Venoso Central/efectos adversos , Niño , Preescolar , Infección Hospitalaria/tratamiento farmacológico , Farmacorresistencia Microbiana , Contaminación de Equipos , Fluconazol/uso terapéutico , Fungemia/tratamiento farmacológico , Hospitales Pediátricos/estadística & datos numéricos , Humanos , Pruebas de Sensibilidad Microbiana , Complicaciones Posoperatorias/tratamiento farmacológico , Eslovaquia , Especificidad de la Especie , Derivación Ventriculoperitoneal/efectos adversosRESUMEN
The aim of this prospective study on fungemia in children with cancer compared with adults with cancer appearing during the last 10 years in a pediatric hospital and in national cancer institutions was to investigate risk factors, etiology, therapy, complications and outcome. Univariate analysis showed significant differences in 35 children with cancer and fungemia in comparison with 130 cases of fungemias in adults with cancer. It was found that (1) therapy with corticosteroids (40 vs 18.5%, P<0.03), (2) breakthrough fungemia during ketoconazole prophylaxis (20 vs 7.7%, P<0.025), and (3) meningitis as a complication of fungemia (11.4 vs 0.8%, P< 0.001) occurred more frequently in the pediatric subgroup with fungemia. Candida albicans was more common as the causative agent of fungemia among adults (58.5 vs 37.1, P<0.02) than in children. However, mortality was similar in children with cancer and in adults with cancer and fungemia (31.4 vs 23.1%, NS). Comparison of risk factors revealed no differences between adults and children with cancer and fungemia except in etiology, breakthrough fungemia during prophylaxis with ketoconazole, prior therapy with corticosteroids and meningitis as a complication. The outcome was also similar in pediatric and adult cancer patients with fungal bloodstream infection.
Asunto(s)
Antifúngicos/uso terapéutico , Fungemia , Neoplasias/complicaciones , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Candida albicans/aislamiento & purificación , Candida albicans/patogenicidad , Candidiasis/epidemiología , Candidiasis/etiología , Candidiasis/terapia , Niño , Preescolar , Femenino , Fungemia/epidemiología , Fungemia/etiología , Fungemia/terapia , Hospitales Pediátricos/estadística & datos numéricos , Humanos , Incidencia , Lactante , Cetoconazol/uso terapéutico , Masculino , Meningitis/etiología , Meningitis/microbiología , Neoplasias/microbiología , Estudios Prospectivos , Factores de Riesgo , Resultado del TratamientoRESUMEN
In a group of 102 children with different immunological subtypes of acute leukemia, both lymphoblastic and nonlymphoblastic, the clinical parameters - event free survival and overall survival were correlated with numerical and structural chromosomal abnormalities. In a group of 80 ALL patients genetic abnormalities were observed in 40 patients, from those 19 of numerical type, 17 of structural type and 4 with both, numerical and structural anomalies. From the whole ALL group observed 23 patients (28.75%) died. In 10 died patients genetic abnormalities were found and in 6 cases less mature T-phenotype ALL has been documented. It seems, therefore, that immature T-phenotype with pathological karyotypes of all types of genetic anomalies presents the most risk group of patients of which all children died. ALL patients, as a whole, with pathological karyotype have shown significantly lower event free survival rate, comparing to the group of ALL patients with normal karyotype. Overall survival rate was also lower in the first group, but statistically not significant. In T-ALL patients, in both groups, with and without pathological karyotype, event free survival rate and overall survival rate were also lower in the first group, but statistically not significant. In B-ALL patients with pathological karyotypes vs. normal ones overall survival rate was lower in the first group, but statistically not significant. There was no difference in overall survival rate in these patients between pathological and normal karyotypes. In ANNL group of patients pathological karyotype was observed in 14 of them, with numerical anomalies in 6 patients, structural in 4 patients and both of them - numerical + structural in 4 children. From the whole ANLL group observed 11 (50%) patients died during the follow-up period (9 in relapse and 2 of treatment complications). From 11 died patients in 81.8% pathological karyotype was present. The prevalence of pathological karyotypes was observed in less mature M0-M2 ANLL subtype (71.4%). ANLL patients with pathological karyotype have shown significantly lower event free survival rate (in one of the two statistical log-rank analyses), comparing to the group of ANLL patients with normal karyotype. Overall survival rate was also lower in the first group, but statistically not significant. The presence/absence of CD34 marker expression in blast cells of our group of acute leukemia patients did not show any difference in event free survival and overall survival rates.
Asunto(s)
Linfoma de Burkitt/mortalidad , Aberraciones Cromosómicas , Trastornos de los Cromosomas , Supervivencia sin Enfermedad , Inmunofenotipificación , Leucemia Mieloide Aguda/mortalidad , Leucemia-Linfoma de Células T del Adulto/mortalidad , Adolescente , Linfoma de Burkitt/genética , Linfoma de Burkitt/inmunología , Niño , Preescolar , Femenino , Citometría de Flujo , Humanos , Lactante , Cariotipificación , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/inmunología , Leucemia-Linfoma de Células T del Adulto/genética , Leucemia-Linfoma de Células T del Adulto/inmunología , Masculino , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Profilaxis Antibiótica , Antifúngicos/uso terapéutico , Candida/patogenicidad , Candidiasis/fisiopatología , Fungemia/fisiopatología , Cetoconazol/uso terapéutico , Adulto , Candidiasis/epidemiología , Niño , Femenino , Fungemia/epidemiología , Humanos , Incidencia , Masculino , Neoplasias/complicacionesRESUMEN
We present 5-year results of treatment in 93 children suffering from acute lymphoblastic leukemia using two therapeutic protocols containing multidrug chemotherapy including high dose methotrexate. We could ascertain different results in standard and high risk patients. In a group of 62 children with standard risk we observed improvement in complete remission rate being 98.9% after induction phase of therapy, only one patient died on septicemia. Relapse rate in this group was 21.2% and that 14.7% in the bone marrow and 6.5% in CNS and no testicular relapse at all. In the group of 31 children with high risk leukemia all patients achieved complete remission. Only one of them died on acute pancreatitis due to toxicity. Overall relapse rate in this group was 28.9% with 12.8% of medullary relapse and 16.1% of CNS relapse. The last one was significantly higher than in the previous study when brain irradiation was a part of therapeutic procedure. It seems that this treatment is effective mainly in the standard risk leukemia, however, in the high risk leukemias this procedure appears to be less effective in preventing CNS leukemia. In this group of patients irradiation of the brain need to be enclosed in the therapy.